

Cyclopharm Limited Annual General Meeting

1 May 2008

Chairman's Welcome



Welcome to the Annual General Meeting of Cyclopharm Limited





Business

Managing Director's Review

Question Time

Close

Proxy Summary



Resolution	Business	For	Against	Abstain
1	Remuneration Report	65,461,653	56,814	5,000
2	Election of Director	46,683,828	-	18,839,639
3	Dividend Reinvestment Plan	65,468,961	28,819	25,687

*Includes Open Useable Proxies that have instructed the Chairman to vote on their behalf and have been voted in favour of the resolution.





Business

Managing Director's Review

Question Time

Close





- Strong balance sheet
- Strong trading cashflow
- Development and implementation of Molecular Imaging division progressing well
- \blacksquare Strong underlying performance of the Technegas division
- Future growth of the business underpinned by capital investment by customers in TechnegasPlus generators
- \blacksquare Cyclopharm well positioned for maintainable profits and future success





Our aim is to be the leading nuclear medicine company in the region

Nuclear Medicine



Nuclear Medicine relies on diagnostic radiotracers to detect and monitor various disease states for oncology, cardiology and neurology.

Key characteristics:

Non invasive (provides a view of the "inside" without surgery)

Safe, painless, cost effective

Provides information on major organs of the body

Approx 100 types of procedure available

Radiation dose comparable to a diagnostic x-ray

Nuclear medicine is experiencing significant growth driven by PET

Positron Emission Tomography ("PET") allows physicians to differentiate between healthy and diseased tissue and therein:

Detect cancer more accurately

Detect cancer earlier than conventional methods

Identify the stage of the disease

Improved therapy prescription

Better monitoring of the therapy effectiveness

Ultimately better patient care









PET Central Pharmacies

New South Wales

Construction of the first PET Central Pharmacy has commenced at the Macquarie-Dalcross Private Hospital in North Ryde, New South Wales.

Victoria

Purchased site and completing design for a purpose built PET Central Pharmacy in Kensington, Victoria. The site is in close proximity to major hospitals.










PET Pharmacy – Greater Sydney



Cyclopharm's PET Central Pharmacy for the Greater Sydney Area is to be located within the Macquarie Dalcross Private Hospital, North Ryde. The immediate catchment area and potential customers for the Company's products is shown on the adjacent map.

Macquarie Dalcross Private Hospital


Sydney

- 1 Central Coast Hospital
- 2 Liverpool Hospital
- 3 Macquarie Hospital
- 4 Mater Hospital
- 5 Prince of Wales Hospital
- 6 Royal North Shore Hospital
- 7 Royal Prince Alfred
- 8 St Vincents Hospital
- 9 Sydney Adventist Hospital
- 10 Westmead Hospital
- 11 Woolongong Hospital





PET Pharmacy – Greater Melbourne



Cyclopharm's PET Central Pharmacy for the Greater Melbourne Area is to be located at a purpose built facility in Llloyd Street Kensington. The immediate catchment area and potential customers for the Company's products is shown on the adjacent map.

Llloyd Street Kensington

- Melbourne
- 1 Alfred Hospital
- 2 Austin Hospital
- 3 MIA Moorabbin
- 4 Monash Medical Centre
- 5 Peter McCallum Hospital
- 6 Royal Childrens Hospital
- 7 Royal Melbourne Hospital
- 8 St Vincents Hospital
- 9 Western General Hospital






Industry Developments

Major industry participants developing molecular imaging strategies – the development of PET/CT capable machines continues to influence market in a positive way

Industry submission to Government to expand the number of indications for rebate – progressing. Existing arrangements extended to 30 June 2008



Industry Developments (continued)

In 2001 - 15 indications approved for rebate for 7 camera's

In 2005 any institution that met government guidelines could claim 3 rebates

In 2007 government widened eligibility criteria and extended existing agreement until 30 June 2008

30,000 patients studied over 25 months to 15 April 2005 – concluded compelling case for PET

Cyclopharm's PET pharmacies to contribute to industry growth







Full Year ending	31 December	2005	2006	2007
Sales Revenue	\$'000	8,806	10,332	11,128
NPAT	\$'000	1,582	2,028	1,131
EPS	cents	1.48	1.87	0.83

Strong annual sales growth and strong cash flow

EPS negatively impacted by:

Delay in regulatory approval in key growth markets

Establishment of Molecular Imaging division

One off costs

Higher operating costs of listed company



Strong Balance Sheet Working capital increase 119% Current liabilities down 64% Total liabilities down 62% Net Assets increased 1397%


Conservatively geared

Balance Sheet Summary	31 December 2007	31 December 2006
Cash and receivables	5,183,393	4,848,450
Inventory	2,348,074	2,013,488
Other	232,262	148,606
Total Current Assets	7,763,729	7,010,544
Non Current Assets	3,213,820	2,195,702
Total Assets	10,977,549	9,206,246
Trade and other payables	1,252,937	3,994,116
Other	331,981	426,442
Total Current Liabilities	1,584,918	4,420,558
Total Non Current Liabilities	2,050,487	5,351,748
Total Liabilities	3,635,405	9,772,306
Net Assets	7,342,144	(566,060)



Sales revenue

Cyclopharm expects growth in Technegas sales revenue to continue










Regional Analysis

Strong growth in Europe from France, Germany and other European countries





France, PAS Revenue




Europe-Other revenue



Regional Analysis

Canada continues to be our star performer with revenue growth 38%.We expect continued growth of 30% in 2008.

We expect further recovery and continued growth in Asian markets








Variance Analysis to Prior Year

Full Year Ending 31 December	2007	2006	Variance
Salaa yaluma			
Sales volume	440	00	0.4
Generators (sold)	113	89	24
Patient Administration Sets	176,700	166,950	9,750
Sales revenue			
Generators	2,825,405	2,234,684	590,721
Patient Administration Sets	8,302,819	8,097,145	205,674
Other	101,406	10,856	90,550
Total Sales	11,229,630	10,342,685	886,945
Cost of materials and manufacturing	(3,121,919)	(2,858,063)	(263,856)
Operating Expenses	(6,494,366)	(4,858,458)	(1,635,908)
Earnings before interest and tax	1,613,345	2,626,164	(1,012,819)





Technegas continues to grow but impacted by one off costs associated with product launch and regulatory approval.(\$370,000)

	2007	2006
For the year ended 31 December	\$	\$
Technegas Division		
Revenue	11,143,379	10,331,832
Profit before income tax	2,642,767	2,665,360
Molecular Imaging		
Revenue	-	-
Profit before income tax	(399,304)	(114,938)
Corporate		
Revenue	86,251	10,856
Profit before income tax	(853,725)	(211,115)
Consolidated		
Revenue	11,229,630	10,342,688
Profit before income tax	1,389,737	2,339,307



Cost of Materials Variance Analysis

Full Year Ending 31 December	2007	2006	Variance
Cost of materials and manufacturing	(3,121,919)	(2,858,063)	(263,856)

Whilst the cost of raw materials to manufacture generators increased 14% overall margins from the sale of Technegas products were consistent with 2006.

CYC did not look to pass the increased cost to customers Cyclopharm manufactured and sold more generators than Prospectus forecast resulting in a higher cost incurred.




Operating Expenses Variance Analysis

Full Year Ending 31 December	2007	2006	Variance
Legal Patent & Other	(845,650)	(486,766)	(358,884)
One off Legal Patent & Other expenses			(288,585)
Increase Audit, compliance and shareregistry costs Other			(62,253) (8,000)
			(358,838)
Office & Facility costs	(802,665)	(563,169)	(239,496)
Insurance			(70,227)
ASX listing fees			(34,088)
Annual Report - publishing & printing			(45,024)
Media			(7,000)
Equipment write off			(32,000)
Other			(51,157)
			(239,496)
Consumable costs			(145,366)
Increase Employee Benefits Expenses			(856,630)
Increase Freight & Delivery costs			(160,417)
Increase Depreciation and Amortisation			(84,411)
Other costs			89,908
Operating Expenses	(6,494,366)	(4,858,458)	(1,635,908)



Cash Receipts

Cyclopharm continues to generate strong positive cash flow





For the 3 months ending 31 March	2007 \$'000	2008 \$'000
Sales revenue	2,018	2,038
OPEX	(1,377)	(1,133)
EBIT	(391)	192

Cyclopharm expect strong sales and profit from Italy, Russia, Canada, France, Germany et al by year end.

Comment on Year End Forecast





Strong positive cash flow

Technegas continues to grow

Molecular imaging continues to develop

Certain 2007 costs are non-recurring (e.g. new product registration and name change)

Year end EBIT forecast of \$2.0+ million




New Drug Application (NDA)

Phase III clinical trials finalised in October 2007

Certus International together with Dr Robert Wolfangel are preparing our NDA submission

Submission of NDA scheduled for June 2008

Approval expected in late 2009





Italy

Registration of medical reimbursement received in December 2007. Significant sales growth expected in 2008.

Russia

First sales of Technegas to a luminary nuclear medical site in Russia. There are in excess of 700 nuclear medicine sites in Russia. Significant growth expected from this market



Brazil

Pursuing regulatory approval in Brazil which has 350 nuclear medicine sites - approval delayed expected in 1H2008.

Mexico

Achieved regulatory approval in Mexico. Three generators have been sold. 50 nuclear medicine sites in Mexico City.



Asia

We achieved 62% growth in Asia for PAS. We will continue to invest in developing Asian markets

Other

We continue to develop our new markets in Tunisia and Oman, Panama, Dominican Republic, Columbia, Peru and Venezuela.

We have made inroads into Argentina, Uruguay, Chile and Costa Rica.



Cyclopharm has entered the next phase of development

Mr Sharman intends to step aside from his role as Managing Director but will continue as a non-executive director

A Managing Director with radiopharmaceutical experience has been identified and the Board is hoping to make an announcement soon.





Focus on NDA submission to sell Technegas in United States

Construction of PET Pharmacy in North Ryde, NSW has commenced

Another record sales year expected

New Managing Director with radiopharmaceutical experience to commence in 2008

Radiopharmaceuticals improve the quality of life for people afflicted with life threatening diseases.





Business

Managing Director's Review

Question Time

Close





Business

Managing Director's Review

Question Time

Close